TrialPharmacology research & perspectives2022

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration.

Nadia Zakaria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.